Ella Fung
Founder
RD
Rosalind Dx
Rosalind Dx develops proprietary technology for prenatal testing that enhances diagnostic accuracy and reduces costs, making these services accessible to women regardless of their socioeconomic status. The startup addresses the need for affordable prenatal care by providing reliable testing solutions for expectant mothers worldwide.
- Biotechnology
- Digital Health
Updated 7 months ago
Funding
Raised to date
$120KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current prenatal testing methods can be expensive and inaccessible, creating disparities in healthcare access for women of varying socioeconomic backgrounds. This limits the ability to detect potential health issues early in pregnancy, potentially impacting maternal and fetal health outcomes.
Solution
Rosalind Dx is developing novel prenatal testing technology designed to improve diagnostic accuracy and reduce overall costs. By leveraging proprietary innovations, the company aims to make advanced prenatal screening more readily available to a broader population of expectant mothers, regardless of their financial circumstances. The company focuses on providing reliable and affordable testing solutions to improve prenatal care accessibility worldwide.
Target Audience
The primary target audience includes expectant mothers and healthcare providers seeking affordable and reliable prenatal testing solutions.
Features
- Proprietary technology for enhanced diagnostic accuracy in prenatal testing
- Focus on cost reduction to improve accessibility